287 related articles for article (PubMed ID: 33928380)
1. Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19.
Lo Sasso B; Gambino CM; Scichilone N; Giglio RV; Bivona G; Scazzone C; Muratore R; Milano S; Barbagallo M; Agnello L; Ciaccio M
Lab Med; 2021 Sep; 52(5):493-498. PubMed ID: 33928380
[TBL] [Abstract][Full Text] [Related]
2. The vasoactive peptide MR-pro-adrenomedullin in COVID-19 patients: an observational study.
Gregoriano C; Koch D; Kutz A; Haubitz S; Conen A; Bernasconi L; Hammerer-Lercher A; Saeed K; Mueller B; Schuetz P
Clin Chem Lab Med; 2021 Apr; 59(5):995-1004. PubMed ID: 33554516
[TBL] [Abstract][Full Text] [Related]
3. High levels of mid-regional proadrenomedullin in ARDS COVID-19 patients: the experience of a single, Italian Center.
Benedetti I; Spinelli D; Callegari T; Bonometti R; Molinaro E; Novara E; Cassinari M; Frino C; Guaschino R; Boverio R; Lauritano EC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1743-1751. PubMed ID: 33629344
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: An observational prospective study.
Montrucchio G; Sales G; Rumbolo F; Palmesino F; Fanelli V; Urbino R; Filippini C; Mengozzi G; Brazzi L
PLoS One; 2021; 16(2):e0246771. PubMed ID: 33556140
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of midregional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsis.
Bernal-Morell E; García-Villalba E; Vera MDC; Medina B; Martinez M; Callejo V; Valero S; Cinesi C; Piñera P; Alcaraz A; Marin I; Muñoz A; Cano A
J Infect; 2018 Mar; 76(3):249-257. PubMed ID: 29246637
[TBL] [Abstract][Full Text] [Related]
6. MR-proADM as marker of endotheliitis predicts COVID-19 severity.
García de Guadiana-Romualdo L; Calvo Nieves MD; Rodríguez Mulero MD; Calcerrada Alises I; Hernández Olivo M; Trapiello Fernández W; González Morales M; Bolado Jiménez C; Albaladejo-Otón MD; Fernández Ovalle H; Conesa Hernández A; Azpeleta Manrique E; Consuegra-Sánchez L; Nogales Martín L; Conesa Zamora P; Andaluz-Ojeda D
Eur J Clin Invest; 2021 May; 51(5):e13511. PubMed ID: 33569769
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia.
Suberviola B; Castellanos-Ortega A; Llorca J; Ortiz F; Iglesias D; Prieto B
Swiss Med Wkly; 2012; 142():w13542. PubMed ID: 22430899
[TBL] [Abstract][Full Text] [Related]
8. Association of midregional proadrenomedullin with coronary artery stenoses, soft atherosclerotic plaques and coronary artery calcium.
Roos M; Schuster T; Ndrepepa G; Baumann M; Lutz J; Braun S; Martinof S; Schömig A; Heemann U; Kastrati A; Hausleiter J
Heart Vessels; 2012 Jul; 27(4):352-9. PubMed ID: 21725669
[TBL] [Abstract][Full Text] [Related]
9. MR-proADM as a Prognostic Marker in Patients With ST-Segment-Elevation Myocardial Infarction-DANAMI-3 (a Danish Study of Optimal Acute Treatment of Patients With STEMI) Substudy.
Falkentoft AC; Rørth R; Iversen K; Høfsten DE; Kelbæk H; Holmvang L; Frydland M; Schoos MM; Helqvist S; Axelsson A; Clemmensen P; Jørgensen E; Saunamäki K; Tilsted HH; Pedersen F; Torp-Pedersen C; Kofoed KF; Goetze JP; Engstrøm T; Køber L
J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29776961
[TBL] [Abstract][Full Text] [Related]
10. MR-proADM as prognostic factor of outcome in COVID-19 patients.
Sozio E; Tascini C; Fabris M; D'Aurizio F; De Carlo C; Graziano E; Bassi F; Sbrana F; Ripoli A; Pagotto A; Giacinta A; Gerussi V; Visentini D; De Stefanis P; Merelli M; Saeed K; Curcio F
Sci Rep; 2021 Mar; 11(1):5121. PubMed ID: 33664308
[TBL] [Abstract][Full Text] [Related]
11. Identification of COVID-19 patients at risk of hospital admission and mortality: a European multicentre retrospective analysis of mid-regional pro-adrenomedullin.
Sozio E; Moore NA; Fabris M; Ripoli A; Rumbolo F; Minieri M; Boverio R; Rodríguez Mulero MD; Lainez-Martinez S; Martínez Martínez M; Calvo D; Gregoriano C; Williams R; Brazzi L; Terrinoni A; Callegari T; Hernández Olivo M; Esteban-Torrella P; Calcerrada I; Bernasconi L; Kidd SP; Sbrana F; Miguens I; Gordon K; Visentini D; Legramante JM; Bassi F; Cortes N; Montrucchio G; Di Lecce VN; Lauritano EC; García de Guadiana-Romualdo L; González Del Castillo J; Bernal-Morell E; Andaluz-Ojeda D; Schuetz P; Curcio F; Tascini C; Saeed K
Respir Res; 2022 Aug; 23(1):221. PubMed ID: 36031619
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission.
Gonzalez Del Castillo J; Wilson DC; Clemente-Callejo C; Román F; Bardés-Robles I; Jiménez I; Orviz E; Dastis-Arias M; Espinosa B; Tornero-Romero F; Giol-Amich J; González V; Llopis-Roca F;
Crit Care; 2019 Oct; 23(1):335. PubMed ID: 31665092
[TBL] [Abstract][Full Text] [Related]
13. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia.
Huang DT; Angus DC; Kellum JA; Pugh NA; Weissfeld LA; Struck J; Delude RL; Rosengart MR; Yealy DM
Chest; 2009 Sep; 136(3):823-831. PubMed ID: 19363212
[TBL] [Abstract][Full Text] [Related]
14. Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the AtheroGene study.
Wild PS; Schnabel RB; Lubos E; Zeller T; Sinning CR; Keller T; Tzikas S; Lackner KJ; Peetz D; Rupprecht HJ; Bickel C; Morgenthaler NG; Papassotiriou J; Tiret L; Münzel T; Blankenberg S
Clin Chem; 2012 Jan; 58(1):226-36. PubMed ID: 22065157
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Mid-Region Proadrenomedullin and In Vitro Interferon Gamma Production for In-Hospital Mortality in Patients with COVID-19 Pneumonia and Respiratory Failure: An Observational Prospective Study.
Mangioni D; Oggioni M; Chatenoud L; Liparoti A; Uceda Renteria S; Alagna L; Biscarini S; Bolis M; Di Modugno A; Mussa M; Renisi G; Ungaro R; Muscatello A; Gori A; Ceriotti F; Bandera A
Viruses; 2022 Jul; 14(8):. PubMed ID: 36016305
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.
Krüger S; Ewig S; Giersdorf S; Hartmann O; Suttorp N; Welte T;
Am J Respir Crit Care Med; 2010 Dec; 182(11):1426-34. PubMed ID: 20639437
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of midregional proadrenomedullin to predict poor outcome in patients with community acquired pneumonia.
Gordo-Remartínez S; Calderón-Moreno M; Fernández-Herranz J; Castuera-Gil A; Gallego-Alonso-Colmenares M; Puertas-López C; Nuevo-González JA; Sánchez-Sendín D; García-Gámiz M; Sevillano-Fernández JA; Álvarez-Sala LA; Andueza-Lillo JA; de Miguel-Yanes JM
PLoS One; 2015; 10(6):e0125212. PubMed ID: 26030588
[TBL] [Abstract][Full Text] [Related]
18. Midregional proadrenomedullin (MR-proADM) in the risk stratification of patients with acute pulmonary embolism.
Pedowska-Włoszek J; Kostrubiec M; Kurnicka K; Ciurzynski M; Palczewski P; Pruszczyk P
Thromb Res; 2013 Nov; 132(5):506-10. PubMed ID: 24060192
[TBL] [Abstract][Full Text] [Related]
19. Endothelial dysfunction and Mid-Regional proAdrenomedullin: What role in SARS-CoV-2 infected Patients?
Zaninotto M; Mion MM; Marchioro L; Padoan A; Plebani M
Clin Chim Acta; 2021 Dec; 523():185-190. PubMed ID: 34555411
[TBL] [Abstract][Full Text] [Related]
20. Biomarker guided triage can reduce hospitalization rate in community acquired febrile urinary tract infection.
Stalenhoef JE; van Nieuwkoop C; Wilson DC; van der Starre WE; Delfos NM; Leyten EMS; Koster T; Ablij HC; Van't Wout JJW; van Dissel JT
J Infect; 2018 Jul; 77(1):18-24. PubMed ID: 29807091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
